MYD88 and B-cell chronic lymphocytic leukemia: Except for MYD88, mutations were significantly more frequent in U-CLL (Fig. 1B), advanced-stage patients (except for NFKBIE mutations) and patients requiring treatment (Supplementary Table S2).